Journal article

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment The FIELD Study

Ru-Dee Ting, Anthony C Keech, Paul L Drury, Mark W Donoghoe, John Hedley, Alicia J Jenkins, Timothy ME Davis, Seppo Lehto, David Celermajer, R John Simes, Kushwin Rajamani, Kim Stanton

Diabetes Care | AMER DIABETES ASSOC | Published : 2012


Funding Acknowledgements

The FIELD Study was supported by grants from Laboratoires Fournier SA, Dijon, France (now part of Abbott Pharmaceuticals), and the National Health and Medical Research Council (NHMRC) of Australia.R.-D.T., A.C.K., T.M.E.D., R.J.S., and K.R. have received speaker's bureau fees from Solvay (now Abbott Pharmaceuticals). A.C.K., P.L.D., A.J.J., T.M.E.D., and R.J.S. have received travel and/or research grant support from Solvay (now Abbott Pharmaceuticals). No other potential conflicts of interest relevant to this article were reported.